|
|
|
市場調查報告書
品牌和策略：阿茲海默症
Brands & Strategies: Alzheimer's Disease
|
品牌和策略：阿茲海默症 是由出版商Decision Resources, Inc.在2008年06月所出版的。
這份英文市場調查報告書包含271 Pages 價格從美金20250起跳。
2007年、阿茲海默症市場在美國、歐洲、日本營收都超過30億美金。是由Eisai／Pfizer的Aricept所帶起。整個成長率鈍化、非專利醫療藥品和新興藥劑處於嚴厲的競爭環境之下，對今後的市場來說會有很大的商機。
本報告書內容包括：阿茲海默症市場的動向和主要企業的概要、醫師對品牌的見解以及至2012年為止的銷售預測、內容綱要摘記如下。
實施摘要
第1章 介紹
第2章 競爭分析
- 競爭環境概要
- 醫師對主要品牌的認知
- 主要品牌表示
- 主要品牌價格比較
- 補貼問題
- 促銷費用
- 各企業動向
- 各品牌動向
- 阿茲海默症品牌宣傳對醫師和醫療人員的見解
第3章 對主要利害關係人的調查
第4章 既有競爭企業
- Pfizer
- エーザイ
- Novartis
- Johnson & Johnson
- Forest Laboratories
- Lundbeck
第6章 既有競爭企業
- Wyeth
- Elan
- Eli Lilly
- Medivation
第7章 市場預測
- 阿茲海默症市場分析
- 各地區銷售
- 各等級的市場占有率
- 各品牌的銷售：目前可能的治療法
- 各品牌的銷售：新興的治療法
- 各企業的銷售
附錄
Abstract
Introduction
In 2007, the Alzheimer' s disease (AD) market, valued at more than $3 billion
in the United States, Europe, and Japan, was led by sales of Eisai/Pfizer' s
Aricept. The growth of all the currently available agents will decline by the
end of our forecast, a combined effect of generic entry and competition from
newly emerging agents. Significant unmet clinical need exists and provides an
attractive commercial opportunity for new AD treatments that demonstrate
superior efficacy over currently available treatments, with the greatest
opportunities for agents demonstrating disease modification. Four new
therapies - Elan/Wyeth' s bapineuzumab, Eli Lilly' s LY-2062430,
Myriad/Lundbeck' s Flurizan, and Medivation' s Dimebon - are set to enter the
market by 2012. The launch of these drugs will shift the AD treatment
landscape away from traditional symptomatic therapies and toward
higher-priced, innovative disease-modifying agents. As AD treatment patterns
shift, physician education and awareness of these emerging factors will be a
critical step in their adoption. By the end of our study period, bapineuzumab
will dominate the AD market, and its growth will help drive the market to
reach $3.9 billion in 2012.
Questions Answered in This Report
- In 2007, the AD market was dominated by Aricept' s makers, Eisai and
Pfizer, commanding more than half of the AD market share. How have Eisai
and Pfizer secured such a dominant market share for Aricept? How will Eisai
and Pfizer fare in the market following the patent expiry of their leading
brand? What can the emerging competitors learn from Eisai and Pfizer' s
strategies to ensure the successful promotion of their novel agents in the AD
market?
- With novel therapies emerging, product marketing will be central to agent
uptake. Our primary research indicates that physicians and AD patient
caregivers respond to a discrete set of information channels. What sources
of marketing spend provide the highest return? Do physicians and caregivers
respond to different channels of information? Which brand messages resonate
and which are forgettable?
- Physicians have long favored Aricept as their AD agent of choice. Why
do physicians favor Aricept, and what do physicians think about the attributes
of other currently marketed agents? What are the perceived advantages and/or
disadvantages of emerging therapies versus available therapies?
- Wyeth/Elan' s bapineuzumab is expected to become an AD blockbuster and has
the potential to radically change the AD market dynamics. Which emerging
drugs have the potential to compete with bapineuzumab? What is the annualized
forecast for current and emerging AD brands? What strategies will Elan and
Wyeth pursue to secure a dominant market position in AD by the end of the
forecast period?
- Four new agents will enter the AD market by 2012: Elan/Wyeth' s
bapineuzumab, Eli Lilly' s LY-2062430, Myriad/Lundbeck' s Flurizan, and
Medivation' s Dimebon. Three of these agents have potential disease modifying
activity. How will the availability of these novel agents alter physicians'
prescribing habits? Which competing brands will be most affected?
Scope
- Markets Covered: United States, France, Germany, Italy, Spain,
United Kingdom, and Japan.
- Competitive Analysis: Detailed discussion of major competitors,
including Pfizer, Eisai, Novartis, Johnson & Johnson (Ortho-McNeil Neurologics
and Janssen), Lundbeck, and Forest Laboratories; discussion of emerging
competitors, including Wyeth, Elan, Myriad Genetics, Eli Lilly, and
Medivation, with an analysis of each company' s Alzheimer' s disease product
portfolio, strategic positioning, and development pipeline. The report
features an in-depth discussion of leading brands, sales and market position,
strengths/weakness/opportunities/threats (SWOT) analysis, ongoing
postmarketing clinical trials, and strategic initiatives.
- Physician Perception of Key Brands: Analysis of physician
perceptions of the Alzheimer' s disease market based on a custom survey of 50
U.S.-based physicians. The survey is brand-focused and examines physician
perceptions of key competitors, brand attributes, messaging, and uptake of
emerging agents.
- Caregiver Perception of Key Brands: Analysis of caregiver
perceptions of the Alzheimer' s disease market based on a custom survey of 134
Alzheimer' s patient caregivers. The survey is brand-focused and examines
caregiver' s perceptions of current brands, response to messaging, and unmet
needs.
- Epidemiology: Total prevalent and diagnosed cases for Alzheimer' s
disease in each of the major markets under study are presented for 2007 and
2012. Total drug-treated Alzheimer' s disease cases in each of the major
markets are presented in an annualized forecast from 2007 to 2012.
- Market Forecast: Annualized sales forecasts for branded agents,
including the uptake of new agents, presented by region, indication,
formulation, and brand from 2007 to 2012.
Table of Contents
Executive Summary
- 2007-2012 Market Dynamics
- Competitive Landscape
- Brand Overview
- Physician and Patient Perspectives: Findings of Our Primary Research
Chapter 1. Introduction
- Scope of the Report
- Survey Methodology
- Physician Demographics
- Patient Demographics
Chapter 2. Competitive Analysis
- Overview of Competitive Landscape
- Physician Perception of Key Brands
- Current Therapies
- Emerging Therapies
- Comparative Labeling for Key Brands
- Comparative Pricing of Key Brands
- Reimbursement Issues
- United States
- Europe
- Japan
- Promotional Spending
- Company-Specific Trends
- Brand-Specific Trends
- Physician and Caregiver Perceptions of Alzheimer's Brand Promotion
Chapter 3. Primary Research with Key Stakeholders
- Key Findings of Primary Research
- Physicians
- Key Drivers of Prescriber Decisions
- Sources of Information
- Response to Messaging
- Perceptions of Competitors
- Perceptions of Brands
- Unmet Needs in Alzheimer's Disease
- Caregivers
- Response to Messaging
- Perceptions of Brands
- Unmet Needs in Alzheimer's Disease
Chapter 4. Established Competitors
- Pfizer
- Strategic Overview
- Goals and Vision in Alzheimer's Disease
- Alzheimer's Disease Product Portfolio
- Current Positioning
- Physicians Inform Our Analysis
- Market Strategy and Outlook
- Eisai
- Strategic Overview
- Goals and Vision in Alzheimer's Disease
- Alzheimer's Disease Product Portfolio
- Current Positioning
- Physicians Inform Our Analysis
- Market Strategy and Outlook
- Aricept
- Current Positioning
- Physicians Inform Our Analysis
- Aricept Competitive Analysis
- Key Brand Strategies in the Alzheimer's Disease Market
- Lifecycle Management and Future Strategy
- Future Positioning and Outlook
- Novartis
- Strategic Overview
- Goals and Vision in Neuroscience
- Alzheimer's Disease Product Portfolio
- Current Positioning
- Physicians Inform Our Analysis
- Market Strategy and Outlook
- Exelon
- Current Positioning
- Physicians Inform Our Analysis
- Exelon Competitive Analysis
- Key Brand Strategies
- Lifecycle Management and Future Strategy
- Future Positioning and Outlook
- Johnson & Johnson
- Strategic Overview
- J&J Companies Currently Marketing Alzheimer's Disease Products
- Goals and Vision in Alzheimer's Disease
- Alzheimer's Disease Product Portfolio
- Current Positioning
- Physicians Inform Our Analysis
- Market Strategy and Outlook
- Razadyne
- Current Positioning
- Physicians Inform Our Analysis
- Razadyne Competitive Analysis
- Key Brand Strategies
- Lifecycle Management and Future Strategy
- Future Positioning and Outlook
- Forest Laboratories
- Strategic Overview
- Goals and Vision in Alzheimer's disease
- Alzheimer's Disease Product Portfolio
- Current Positioning
- Physicians Inform Our Analysis
- Market Strategy and Outlook
- Lundbeck
- Strategic Overview
- Goals and Vision in Alzheimer's disease
- Alzheimer's Disease Product Portfolio
- Current Positioning
- Market Strategy and Outlook
- Namenda
- Current Positioning
- Physicians Inform Our Analysis
- Namenda Competitive Analysis
- Key Brand Strategies
- Lifecycle Management and Future Strategy
- Future Positioning and Outlook
Chapter 6. Emerging Competitors
- Wyeth
- Strategic Overview
- Goals and Vision in Alzheimer's Disease
- Alzheimer's Disease Product Portfolio
- Elan
- Strategic Overview
- Goals and Vision in CNS
- Alzheimer's Disease Product Portfolio
- Bapineuzumab
- Development and Commercial Overview
- Bapineuzumab Competitive Analysis
- Future Positioning and Outlook
- Eli Lilly
- Strategic Overview
- Goals and Vision in Neuroscience
- Alzheimer's Disease Product Portfolio
- LY-2062430
- Development and Commercial Overview
- LY-2062430 Competitive Analysis
- Future Positioning and Outlook
- LY-450139
- Development and Commercial Overview
- Medivation
- Strategic Overview
- Goals and Vision in Alzheimer's Disease
- Alzheimer's Disease Product Portfolio
- Dimebon
- Development and Commercial Overview
- Dimebon Competitive Analysis
- Future Positioning and Outlook
Chapter 7. Market Forecast
- Alzheimer's Disease Market Analysis
- Sales by Region
- Key Trends in the U.S. Alzheimer's Disease Market, 2007-2012
- Key Trends in the European Alzheimer's Disease Markets, 2007-2012
- Key Trends in the Japanese Alzheimer's Disease Market, 2007-2012
- Market Share by Class
- Sales by Brand: Currently Available Therapies
- Key Trends in Aricept Alzheimer's Disease Sales, 2007-2012
- Key Trends in Exelon Alzheimer's Disease Sales, 2007-2012
- Key Trends in Razadyne Alzheimer's Disease Sales, 2007-2012
- Key Trends in Namenda Alzheimer's Disease Sales, 2007-2012
- Sales by Brand: Emerging Therapies
- Key Trends in Bapineuzumab and LY-2062430 Alzheimer's Disease Sales,
2007-2012
- Key Trends in Dimebon Alzheimer's Disease Sales, 2007-2012
- Sales by Company
- Appendices
- Epidemiology
- Prevalence and Diagnosis
- Major Markets Statistics and Key Findings
- Abbreviations Used in this Report
- Methodology
- Epidemiology
- Market Forecast
- Emerging Therapy Prices
- Companies Included in Competitive Analysis
Table of Exhibits
- Executive Summary
- Exhibit 1: Key Parameters of the Alzheimer's Disease Market
- Exhibit 2: Alzheimer's Disease Market ($US), Major Markets, 2007-2012
- Exhibit 3: Alzheimer's Disease Market Competitive Position, 2007 and 2012
- Exhibit 4: Alzheimer's Disease Market, by Company, as a % of Total, 2007
and 2012
- Exhibit 5: Alzheimer's Disease Sales ($US), as a Percentage of Total, 2007
and 2012
- Exhibit 6: Physician Top-of-Mind Companies in Alzheimer's Disease Treatment
- Exhibit 7: Physician Rankings of Current Alzheimer's Disease Treatments
- Exhibit 8: Caregiver Rankings of Top-of-Mind Alzheimer's Disease Treatments
- Exhibit 9: Surveyed Physicians' Years of Practice
- Exhibit 10: Surveyed Physicians' Patients per Month
- Exhibit 11: Surveyed Physicians' Geographic Distribution
- Exhibit 12: Surveyed Caregivers' Age
- Exhibit 13: Surveyed Caregivers' Gender
- Exhibit 14: Patient Age, Reported by Surveyed Caregiver
- Exhibit 15: Number of Years Caregiver has Taken Care of Alzheimer's
Disease Patient
- Exhibit 16: Number of Years Patient has Received Treatment for Alzheimer's
Disease,
- Reported by Surveyed Caregiver
- Exhibit 17: Patients' Healthcare Provider, Reported by Surveyed Caregiver
- Exhibit 18: Surveyed Patients' Severity of Alzheimer's Disease, Reported
by Caregiver
- Exhibit 19: Surveyed Caregivers' Relationship to Alzheimer's Disease
Patient
- Exhibit 20: Alzheimer's Disease Sales ($MM), by Country, 2007
- Exhibit 21: Alzheimer's Market Competitive Position, by Major Brands, 2007
and 2012
- Exhibit 22: Alzheimer's Disease Major-Market Sales ($MM), 2007-2012
- Exhibit 23: Physician Perception of Key Brands in Alzheimer's Disease
- Exhibit 24: Labeled Indications for Key Brands, 2008
- Exhibit 25: Current Price per Day ($), Key Brands, 2007
- Exhibit 26: Medicare Formulary Status of Leading Alzheimer's Disease Drugs
- Exhibit 27: U.S. Non-Medicare Formulary Status of Leading Alzheimer's
Disease Drugs
- Exhibit 28: Alzheimer's Disease Patients'- Primary Prescription Drug
Coverage, Reported by Surveyed Caregivers
- Exhibit 29: Caregiver Perception of Alzheimer's Disease Drug Pricing
- Exhibit 30: Reimbursement of Leading Alzheimer's Disease Drugs in Europe
and Japan
- Exhibit 31: Promotional Spend for Alzheimer's Disease Therapies, by
Company, 2007
- Exhibit 32: Promotional Spend for Alzheimer's Disease Therapies, by Brand,
2007
- Exhibit 33: Promotional Spending, by Competitor, as a % of Total Spending
for Agents in Alzheimer's Disease, 2006-2007
- Exhibit 34: Physician Perception of the Alzheimer's Drug with the Most
Promotional Material
- Exhibit 35: Advertising Seen by Caregivers, By Brand
- Exhibit 36: Alzheimer's Disease Treatment Patterns, by Major Market
- Exhibit 37: Preferred Information Sources for Physicians Who Treat
Alzheimer's Disease
- Exhibit 38: Sources of Information for Alzheimer's Disease for Caregivers
and Patients, Physician-Ranked
- Exhibit 39: Physician Response to Marketing Messages for a Hypothetical
Alzheimer's Brand
- Exhibit 40: Physician Perception of Most Influential Branded-Drug
Marketing Messages in the Alzheimer's Disease Market
- Exhibit 41: Physicians' Top-of-Mind Companies in Alzheimer's Disease
- Exhibit 42: Physician Rankings of the Current Reputation of Competitors in
the Alzheimer's Disease Market
- Exhibit 43: Physician Rankings of Alzheimer's Competitors, Based on
Currently Marketed Drugs' Attributes
- Exhibit 44: Physician Rankings of Alzheimer's Competitors, Summary
- Exhibit 45: Company Reputations in Alzheimer's Disease Treatment
- Exhibit 46: Physician Rankings of Alzheimer's Brands, Summary
- Exhibit 47: Physician Rankings of Currently Marketed Brands for
Alzheimer's Disease
- Exhibit 48: Physician Rankings of Alzheimer's Brands by Number of Patient
Requests
- Exhibit 49: Physician Perceptions of Unmet Needs in Alzheimer's Disease
- Exhibit 50: Physician Perceptions of Unmet Needs in Alzheimer's Disease
- Exhibit 51: Surveyed Caregivers' Relationship to Alzheimer's Disease
Patients
- Exhibit 52: Surveyed Patients' Severity of Alzheimer's Disease, Reported
by Caregiver
- Exhibit 53: Caregivers' Most-Trusted Sources for Alzheimer's Information
- Exhibit 54: Sources for Alzheimer's Information Used By Caregivers in the
Past Three Months
- Exhibit 55: Sources of Information for Requested Therapies
- Exhibit 56: Caregiver Response to Marketing Messages in Alzheimer's
Disease, Using Hypothetical “Brand X”
- Exhibit 57: Caregiver Perception of Influential Messaging in the
Alzheimer's Disease Market
- Exhibit 58: Caregiver Identification of Brand Messaging in the Alzheimer's
Disease Market
- Exhibit 59: Caregivers Top-of-Mind Alzheimer's Disease Therapies, by Brand
- Exhibit 60: Therapies Specifically Requested by Caregiver for an
Alzheimer's Disease Patient
- Exhibit 61: Alzheimer's Disease Patients'- Therapeutic History, by Brand
- Exhibit 62: Key Drivers of Alzheimer's Therapy Use, by Brand
- Exhibit 63: Reasons for Discontinuation of Alzheimer's Disease Therapies,
by Brand
- Exhibit 64: Caregiver Perception of Unmet Needs in Alzheimer's Disease
- Exhibit 65: Summary of Pfizer's Alzheimer's Disease Product Portfolio
- Exhibit 66: Physician Perceptions of Pfizer in Alzheimer's Disease
- Exhibit 67: Top-of-Mind Companies in Alzheimer's Disease
- Exhibit 68: Summary of Eisai's Alzheimer's Disease Product Portfolio
- Exhibit 69: Physician Perceptions of Eisai in Alzheimer's Disease
- Exhibit 70: Physician Perceptions of Aricept
- Exhibit 71: Currently Marketed AChEI Launch Dates, by Region
- Exhibit 72: The Effect of Aricept's Recent Expansion of Approved
Indications on Physicians' - Prescribing for Moderate to Severe AD Patients
- Exhibit 73: Percentage of Physicians Prescribing AD Drug Regimens
Off-Label to Treat MCI and Vascular Dementia
- Exhibit 74: Reasons Physicians Do Not Prescribe AD Drug Regimens Off-Label
to Treat MCI and Vascular Dementia
- Exhibit 75: Ongoing Eisai/Pfizer-Sponsored Clinical Trials for Aricept
- Exhibit 76: Aricept Alzheimer's Disease Sales ($US), by Region, 2007-2012
- Exhibit 77: Aricept Alzheimer's Disease Sales ($US), by Formulation,
2007-2012
- Exhibit 78: Aricept Alzheimer's Disease Sales, by Country, 2007-2012
- Exhibit 79: Summary of Novartis's Alzheimer's Disease Product Portfolio
- Exhibit 80: Physician Perceptions of Novartis in Alzheimer's Disease
- Exhibit 81: Physician Perceptions of Exelon
- Exhibit 82: Surveyed Physicians Who Prescribe Multiple AChEIs Favor
Specific Brands Second Line
- Exhibit 83: Physicians'- Method of Awareness of FDA Approval of the Exelon
Transdermal Patch
- Exhibit 84: The Effect of Exelon Transdermal Patch Availability in
Physician Prescribing for Mild to Moderate AD Patients
- Exhibit 85: Reasons Why the Exelon Patch May Not Change Prescribing
Behavior
- Exhibit 86: Physicians'- Expected Switching of Patients to Exelon Patch
from Aricept
- Exhibit 87: Physicians'- Reasons for Not Switching Patients to Exelon
Patch from Aricept
- Exhibit 88: Ongoing Novartis-Sponsored Phase III and IV Clinical Trials
for Exelon
- Exhibit 89: Exelon Alzheimer's Disease Sales ($US), By Region, 2007-2012
- Exhibit 90: Exelon Alzheimer's Disease Sales ($US), By Formulation,
2007-2012
- Exhibit 91: Exelon Alzheimer's Disease Sales, ($US) by Country, 2007-2012
- Exhibit 92: Summary of Johnson & Johnson's Alzheimer's Disease Product
Portfolio
- Exhibit 93: Physician Perceptions of Ortho-McNeil Neurologics in
Alzheimer's Disease
- Exhibit 94: Physician Perceptions of Janssen in Alzheimer's Disease
- Exhibit 95: Physician Perceptions of Razadyne
- Exhibit 96: Ongoing Industry-Sponsored Phase III and IV Clinical Trials
for Razadyne/Razadyne ER
- Exhibit 97: Razadyne Alzheimer's Disease Sales ($US), By Region, 2007-2012
- Exhibit 98: Razadyne Alzheimer's Disease Sales ($US), By Formulation,
2007-2012
- Exhibit 99: Razadyne Alzheimer's Disease Sales ($US), by Country, 2007-2012
- Exhibit 100: Summary of Forest Laboratories' Alzheimer's Disease Product
Portfolio
- Exhibit 101: Physician Perceptions of Forest in Alzheimer's Disease
- Exhibit 102: Summary of Lundbeck's Alzheimer's Disease Product Portfolio
- Exhibit 103: Physician Perceptions of Namenda
- Exhibit 104: Physician Use of Namenda in Moderate to Severe AD Patients
- Exhibit 105: Physician Use of Namenda in Mild to Moderate AD Patients
- Exhibit 106: Reasons Physicians Do Not Prescribe Namenda to Moderate to
Severe AD Patients
- Exhibit 107: Ongoing Clinical Trials for Namenda
- Exhibit 108: Namenda Alzheimer's Disease Sales ($US), By Region, 2007-2012
- Exhibit 109: Namenda Alzheimer's Disease Sales ($US), By Formulation,
2007-2012
- Exhibit 110: Namenda Alzheimer's Disease Sales ($US), by Country, 2007-2012
- Exhibit 111: Summary of Wyeth's Top Pharmaceutical Products, 2007
- Exhibit 112: Summary of Wyeth's Alzheimer's Disease Product Portfolio
- Exhibit 113: Summary of Elan's Top Biopharmaceutical Brands, 2007
- Exhibit 114: Summary of Elan's Alzheimer's Disease Product Portfolio
- Exhibit 115: Physicians' Expected Effect of Emerging Drug Classes on AD
Disease Progression
- Exhibit 116: Physicians' Familiarity with Late-Stage Development
Alzheimer's Disease Drugs
- Exhibit 117: Bapineuzumab Alzheimer's Disease Sales ($US), 2007-2012
- Exhibit 118: Expected Bapineuzumab Alzheimer's Disease Sales ($US), by
Country, 2007-2012
- Exhibit 119: Bapineuzumab, Expected Price per Day ($US), by Country
- Exhibit 120: Summary of Eli Lilly's Top Therapeutic Areas
- Exhibit 121: Summary of Eli Lilly's Alzheimer's Disease Product Portfolio
- Exhibit 122: LY-2062430 Alzheimer's Disease Sales ($US), 2007-2012
- Exhibit 123: Expected LY-2062430 Alzheimer's Disease Sales ($US), by
Country, 2007- 2012
- Exhibit 124: LY-2062430, Expected Price per Day ($US), by Country
- Exhibit 125: Summary of Medivation's Development Spend, 2003-2007
- Exhibit 126: Summary of Medivation's Product Development Portfolio
- Exhibit 127: Dimebon's Alzheimer's Disease Sales ($US), 2007-2012
- Exhibit 128: Expected Dimebon Alzheimer's Disease Sales ($US), by Country,
2007- 2012
- Exhibit 129: Dimebon, Expected Price per Day ($US), by Country
- Exhibit 130: Alzheimer's Disease Market ($US), Major Markets, 2007-2012
(Tabular Format)
- Exhibit 131: Alzheimer's Disease Market ($US), Major Markets, 2007-2012
(Graphical Format)
- Exhibit 132: Timeline of Key Events in the Alzheimer's Disease Market
- Exhibit 133: Key Launch Events, Alzheimer's Disease Market, 2007-2012
- Exhibit 134: Expected Generic Entries, Alzheimer's Disease Market,
2007-2012
- Exhibit 135: U.S. Market Dynamics, by Drug Class, 2007-2012
- Exhibit 136: European Market Dynamics for Alzheimer's Disease, by Drug
Class, 2007- 2012
- Exhibit 137: Japanese Market Dynamics in Alzheimer's Disease, by Drug
Class, 2007- 2012
- Exhibit 138: Alzheimer's Disease Market ($US), by Country, 2007-2012
- Exhibit 139: Alzheimer's Market ($US), by Class, 2007 and 2012
- Exhibit 140: Alzheimer's Market ($US), Competitors by Brand, 2007-2012
(Graphical Format)
- Exhibit 141: Alzheimer's Market ($US), Competitors by Brand, 2007-2012
(Tabular Format)
- Exhibit 142: Alzheimer's Market ($US), by Company, 2007-2012
- Exhibit 143: Prevalent and Diagnosed Alzheimer's Disease Cases, Major
Markets, 2007-2012
- Exhibit 144: Diagnosed Alzheimer's Disease Cases, by Country, Major
Markets, 2007- 2012
- Exhibit 145: Prevalent and Diagnosed Alzheimer's Disease Cases, by
Country, Major Markets, 2007-2012
- Exhibit 146: Adjusted Price of Aricept due to Generic Erosion, 2007-2012
- Exhibit 147: Adjusted Price of Razadyne due to Generic Erosion, 2007-2012
- Exhibit 148: Adjusted Price of Exelon due to Generic Erosion, 2007-2012
|
 |
